hrp0098fc1.4 | Diabetes and Insulin | ESPE2024

A personalized approach to classify the degree of liver insulin resistance in children with obesity

Tans Roel , Schipper Anoeska , Kusters Ron , van Mil Edgar

Introduction: Obesity is associated with an increased risk of developing several metabolic disorders, such as type 2 diabetes. The Children’s Lifestyle Medicine Centre at the Jeroen Bosch Hospital is a national reference center for the personalized treatment of children (aged 5-18 years) with severe obesity. As part of this personalized program, patients undergo an extensive oral glucose tolerance test (OGTT), in which both glucose and insulin levels are...

hrp0097p2-133 | Fat, Metabolism and Obesity | ESPE2023

Integrated care for childhood obesity within the medical and municipal domain

van Mil Edgar , Koetsier Leandra , Seidell Jaap , Sijben Marian , Stroo Judith , van der Velde Marian , Halberstadt Jutka

Childhood obesity is a chronic disease with detrimental effects on health and wellbeing. Treatment was traditionally focused on reducing caloric intake and increasing energy expenditure. However, considering the global increase in prevalence in obesity, especially in the paediatric age range, this approach is insufficient and transition to new initiatives is needed. Obesity is a complex disease resulting from the interaction of multiple underlying factors, including personal c...

hrp0098rfc7.5 | GH and IGFs | ESPE2024

Health-related quality of life at mid-puberty in adolescents with idiopathic isolated growth hormone deficiency

Vliegenthart Joeri , van Busschbach Jan , Maarten Wit Jan , Bakker Boudewijn , Boot Annemieke , de Bruin Christiaan , Finken Martijn , van der Heyden Josine , Hokken-Koelega Anita , van der Kamp Hetty , de Kort Sandra , van Mil Edgar , Reedijk Ardine , Sas Theo , Schott Nina , van Setten Petra , Straetemans Saartje , van Tellingen Vera , Touwslager Bob , van Trotsenburg Paul , Voorhoeve Paul , van der Kaay Danielle

Introduction: Health related Quality of Life (QoL) outcome is used as an argument when continuation or stopping growth hormone (GH) treatment is considered in patients with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH sufficient in mid-puberty (inclusion moment for this study).Aim: To assess potential differences in QoL between patients with IIGHD who discontinued treatment and those who continued ...